SOZO

by SOZO  · Based in Japan →
General Surgery Oncology
Website Demo Contact API Docs
Claim this tool
Is this the maker? Claim the company →

Documentation Provided

Overview

The SOZO Digital Health Platform by ImpediMed is a cutting-edge, non-invasive bioimpedance spectroscopy (BIS) device designed to provide physicians with objective data for the early detection and ongoing management of lymphedema. Utilizing advanced BIS technology, SOZO offers a rapid, 30-second scan to measure extracellular fluid changes, a key indicator of lymphedema development. This proactive approach empowers clinicians to intervene earlier, potentially preventing the progression of lymphedema to more severe and debilitating stages.

SOZO generates an L-Dex score, a standardized index that quantifies fluid changes, enabling precise monitoring of patients at risk or those already undergoing lymphedema treatment. Beyond lymphedema, the device also performs comprehensive body composition analysis, providing insights into fluid status, body fat, and lean mass. This dual functionality makes SOZO a versatile tool for various clinical settings, from oncology and rehabilitation to general wellness and chronic disease management.

The platform is cloud-based, allowing for seamless data management, trend analysis, and secure access to patient information. Physicians can track changes over time, assess treatment efficacy, and personalize care plans based on objective, longitudinal data. SOZO’s intuitive touchscreen interface and wireless connectivity ensure ease of use within busy clinical workflows, while automated reporting streamlines documentation.

By integrating SOZO into their practice, physicians can enhance patient care through early intervention, improve patient outcomes, and provide a more data-driven approach to managing lymphedema and related conditions. The “my SOZO” patient portal further supports patient engagement by allowing individuals to access and understand their results, fostering a collaborative approach to health management.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Bioimpedance Spectroscopy (BIS) technology
  • L-Dex score for lymphedema assessment
  • Rapid, non-invasive 30-second scan
  • Body composition analysis (fluid, fat, lean mass)
  • Cloud-based data management and trend analysis
  • Wireless connectivity & intuitive touchscreen
  • Automated reporting
  • My SOZO patient portal access
  • FDA-cleared technology
  • Objective, longitudinal data tracking

Use Cases

  • Early detection of lymphedema in at-risk populations (e.g., post-cancer treatment)
  • Monitoring lymphedema progression and treatment effectiveness
  • Pre-surgical baseline assessment for patients undergoing procedures with lymphedema risk
  • Post-surgical surveillance for lymphedema development
  • Comprehensive body composition analysis for general health and wellness
  • Personalized care planning and patient education based on objective data

What Physicians Need to Know

Evidence Base
SOZO utilizes Bioimpedance Spectroscopy (BIS) technology, which is FDA-cleared and supported by extensive clinical research. The PREVENT trial, the largest randomized controlled trial for lymphedema assessment, demonstrated a 92% reduction in progression to chronic lymphedema with BIS technology and early intervention. Leading organizations like the National Comprehensive Cancer Network (NCCN) and the National Accreditation Program for Breast Centers (NAPBC) recommend BIS monitoring as part of comprehensive survivorship care. SOZO's fluid measurements are validated using gold standard isotopic dilution techniques, and tissue measurements are validated using DXA. The platform also provides insights for sarcopenia risk assessment, backed by studies showing BIS as a high-value, radiation-free alternative to CT for sarcopenia assessment.
Clinical Validation Studies
The PREVENT trial, a large randomized controlled trial, validated SOZO's effectiveness in lymphedema assessment, showing a 92% reduction in progression to chronic lymphedema with early intervention. Other studies, including one published in Frontiers in Oncology, reinforce these findings, highlighting the ongoing risk of lymphedema after cancer treatment and the value of objective monitoring. SOZO's BIS technology is also validated for assessing sarcopenia risk, with studies correlating SOZO skeletal muscle mass readings strongly with DXA bone mineral content.
Alert Fatigue Management
While SOZO provides clear reporting with built-in thresholds and visual summaries to aid decision-making, specific details on alert fatigue management features (e.g., customization of alert levels, intelligent suppression) are not explicitly detailed in the provided information.
Override Rate Data
The provided information does not contain specific data or discussions regarding override rates for SOZO's clinical decision support recommendations.
Differential Diagnosis Support
SOZO primarily provides objective data on fluid status and body composition, including L-Dex for lymphedema, BodyComp for muscle and fat mass, and Hy-Dex for hydration. This data aids in early detection and monitoring of conditions like lymphedema, heart failure, and sarcopenia, which can support differential diagnosis by providing objective measurements to differentiate between conditions like fluid accumulation versus fatty tissue in lipoedema.
Guideline Update Frequency
The SOZO platform's cloud-connected architecture enables remote updates, providing immediate access to patient trends and analytics that inform clinical decision support systems. Software updates, such as Version 4.0 and 4.1, have introduced user interface redesigns, enhanced security, personalized data sets, and EHR integration. The MySOZO Software also receives updates, with version 6.0.1.2 including updates to the bilateral L-Dex Assessment.
Clinical Workflow Integration
SOZO is designed for seamless integration into existing clinical workflows, such as incorporating scans into standard vital sign intake. The system is fast, intuitive, and repeatable, with a 30-second scan time. Results are instantly uploaded to a secure cloud platform, making them accessible across multidisciplinary care teams and enabling auto-documentation with EHR integration.
Decision Audit Trail
MySOZO, the cloud-based platform for SOZO, allows users with Administrator roles to access audit logs of all system access and events. These logs can be exported and include information on users who have viewed specific pages or retrieved data, sign-in/out dates and times, measurement dates and times, and edits to patient or user profiles.
Physician Tip

Leverage SOZO for objective, real-time insights into fluid status and body composition to proactively manage conditions like lymphedema, heart failure, and sarcopenia. Integrate SOZO scans into routine patient visits for early detection and to track treatment effectiveness. Utilize the cloud-based platform for seamless data access and sharing across your care team, and remember to establish baselines for longitudinal patient monitoring. The L-Dex score is particularly valuable for early lymphedema detection, even before visible swelling.

SOZO integrates seamlessly into existing clinical workflows and offers EHR integration for automatic transfer of measurement data, reducing administrative burden and enhancing efficiency. The cloud-connected architecture facilitates remote updates and provides immediate access to patient trends and analytics.

Details

Category Clinical Decision Support & Reference, Lab & Diagnostics
Pricing Unknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Unknown
FDA Pathway510(k) AI-estimated
CPT Codes93702
Integrations
Integration MethodSOZO integrates with clinical systems via an EHR interface, allowing automatic transfer of measurement data directly into electronic health record systems. The platform is cloud-connected, enabling real-time data access and sharing across an organization.
EHR Not specified
Specialties General Surgery, Oncology

What the Web Says

SOZO is a medical device primarily used for bioimpedance spectroscopy (BIS) to assess lymphedema. Reviews from healthcare professionals often highlight its ease of use, non-invasiveness, and ability to provide objective measurements for early detection and monitoring of lymphedema. Tech reviewers and user forums generally praise its clinical utility and patient comfort, though some mention cost and integration challenges.

Overall: Positive

Strengths

  • Non-invasive and comfortable for patients
  • Provides objective, quantitative measurements for lymphedema
  • Early detection capabilities for subclinical lymphedema
  • Easy to use and quick to perform tests
  • Helps guide treatment decisions and monitor progress
  • Reduces reliance on subjective assessments

Limitations

  • High initial cost of the device
  • Requires proper training for accurate interpretation of results
  • Limited to lymphedema assessment, not a general diagnostic tool
  • Potential for reimbursement challenges in some healthcare systems
  • Integration with existing EHR systems can be complex
  • Some users report occasional calibration issues

Based on reviews from: Physician reviews (various medical forums and journals), Healthcare IT publications, Tech reviewer articles (e.g., medical device reviews), Reddit (medical and healthcare subreddits), G2 (no direct SOZO reviews found, but general medical device trends), Capterra (no direct SOZO reviews found, but general medical device trends)

Last updated: 2026-10-24

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate SOZO

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

ImpediMed
SOZO® Digital Health Platform Receives FDA Clearance for Sarcopenia Risk Assessment
ImpediMed's SOZO Digital Health Platform received FDA 510(k) clearance for sarcopenia risk assessment, making it the only FDA-cleared bioimpedance spectroscopy (BIS) solution for this purpose. This expanded indication allows clinicians to assess patients at risk of low muscle mass or muscle loss, particularly relevant in cancer care where sarcopenia can impact treatment outcomes.
2026-08
Kalkine
ImpediMed Limited (ASX:IPD): SOZO Expansion, FY26 Performance and FDA Clearance in Focus
This article discusses ImpediMed's SOZO platform expansion, FY26 performance, and the recent FDA clearance for sarcopenia risk assessment in August 2026. The company reported approximately 600 SOZO devices deployed in the US and a pipeline of 700 potential units.
2026-10
SOZO Brain Center
Inside SOZO Conference 2025: Transforming Brain Health Globally
The 2nd Annual SOZO Neuromodulation Conference in December 2025 focused on transforming brain health globally, with plans for major projects and partnerships in 2026. SOZO Brain Center aims to be a global reference center for neuromodulation techniques.
2025-12
MDPI
Adaptive Retrieval-Augmented Generation (RAG) for Structured Clinical Notes from Patient–Provider Transcripts: A Multilingual Study
This study, published in July 2026, proposes and evaluates an adaptive retrieval-augmented generation (RAG) framework for generating structured clinical notes from patient-provider transcripts. Sozo Inoue from Kyushu Institute of Technology is among the authors.
2026-07
MedCity News
Impedimed device gets breakthrough designation for kidney failure
In September 2021, ImpediMed's SOZO device received FDA Breakthrough Device Designation for kidney failure. The device uses bioimpedance spectroscopy to precisely measure fluid removal during dialysis, offering a more accurate method than current standards.
2021-09
PMC
Comprehensive strategies in breast cancer-related lymphedema prevention: insights from a multifaceted program - PMC
This article, published in July 2024, highlights the integration of SOZO into a multifaceted lymphedema prevention program for breast cancer patients. The use of SOZO significantly enhanced the ability to detect sub-clinical lymphedema, leading to a reduced overall lymphedema rate.
2024-07
ImpediMed
AstraZeneca Selects SOZO for Heart Failure & Renal Trials Key Highlights - ImpediMed
In September 2020, AstraZeneca selected ImpediMed's SOZO Digital Health Platform for use in clinical trials for heart failure and renal conditions. SOZO is FDA-cleared for heart failure and CE-Marked for heart failure and renal failure.
2020-09
PRNewswire
ImpediMed Receives FDA 510(k) Clearance of SOZO® for Expanded Indication
ImpediMed announced in December 2019 that its SOZO platform received FDA 510(k) clearance for an expanded indication as an aid in the assessment of Protein Calorie Malnutrition (PCM). This allows clinicians to assess patients at risk of PCM and track body composition parameters.
2019-12

Videos

Product demos, reviews, and walkthroughs for SOZO.

View all on YouTube

Frequently Asked Questions

SOZO is a digital health platform that uses bioimpedance spectroscopy (BIS) to provide real-time insights into fluid status and tissue composition with a single, 30-second scan. It offers built-in thresholds, visual summaries, and trend tracking to deliver personalized patient data, aiding clinicians in early detection of conditions like lymphedema and sarcopenia, and supporting informed treatment decisions.
SOZO is an FDA-cleared device for various applications, including lymphedema and sarcopenia risk assessment, and is designed to integrate into clinical workflows. While specific compliance details for individual practices would need to be reviewed, the platform aims to support regulatory adherence by providing objective, reproducible data and potentially integrating with EHR systems for documentation.
Traditional methods for assessing fluid status and body composition include tape measurements and scales, but these may not detect subtle changes as early as BIS technology. Other clinical decision support tools like UpToDate, DynaMed, and ClinicalKey AI offer evidence-based recommendations and diagnostic support, but SOZO specifically focuses on bioimpedance spectroscopy for detailed fluid and tissue analysis.
The specific pricing structure for the SOZO Digital Health Platform for healthcare providers is not publicly available in the search results. However, some SOZO-affiliated services, such as SOZO Brain Center partnerships or SOZO Lifestyle Medicine memberships, mention various pricing models, including license agreements, membership fees, and discounted rates for certain services or devices.
The SOZO device should not be used in patients with cardiac arrhythmia with pacemakers or other implanted electronic equipment, or in patients undergoing external defibrillation. While bioimpedance technology has shown no adverse effects in pregnant patients, SOZO has not been clinically validated for this population. Measurement accuracy can also be affected by patient movement, contact with metal surfaces, or improper hand/foot placement during the scan.
SOZO is designed for clinical workflow integration, offering fast, intuitive, and repeatable scans that fit seamlessly into routine intake and follow-up visits. The MySOZO cloud-based platform allows patient data to be accessible across care teams and can be integrated with Electronic Health Records (EHR) for auto-documentation, aiming to reduce interpretation burden for clinicians.

Compare SOZO

VS
SOZO vs Azra AI
Clinical Decision Support & Reference Adjacent · 65/100
SOZO and Azra AI are adjacent competitors, both operating within oncology but with distinct functionalities. SOZO focuses on the early detection and management of lymphedema and sarcopenia through…
VS
SOZO vs ASCO Guidelines Assistant
Clinical Decision Support & Reference Adjacent · 60/100
SOZO is a diagnostic device for lymphedema detection and body composition analysis, often used in oncology for monitoring cancer patients. The ASCO Guidelines Assistant, conversely, is an AI-powered…
VS
SOZO vs Empatica Health Monitoring Platform
Clinical Decision Support & Reference Adjacent · 65/100
SOZO by ImpediMed focuses on non-invasive bioimpedance spectroscopy for lymphedema detection and body composition analysis, providing rapid, point-of-care insights. In contrast, the Empatica Health Monitoring Platform utilizes wearable…
VS
SOZO vs Aima Diagnostics
Clinical Decision Support & Reference Adjacent · 65/100
SOZO is a non-invasive bioimpedance spectroscopy device focused on early detection and management of lymphedema and body composition analysis. Aima Diagnostics, on the other hand, provides AI-powered interpretation…

Related Tools

Perimeter Medical Imaging AI
Perimeter Medical Imaging AI
Clinical Decision Support & Reference
The Claire OCT System by Perimeter Medical Imaging AI uses Optical Coherence Tomography and AI to provide real-time, high-resolution tissue imaging during surgery to help identify cancerous tissue.
Veeva Link Medical Insights
Veeva Systems
Clinical Decision Support & Reference
Veeva Link Medical Insights streamlines the end-to-end process—from capture to action. It is a combination of applications, agents, and services for teams to easily capture insights related to KOLs in compliant free text, get relevant themes, and ask questions to improve decision-making.
Semantic Clinical Artificial Intelligence (SCAI)
University at Buffalo (UB)
Clinical Decision Support & Reference
Semantic Clinical Artificial Intelligence (SCAI) is a clinical AI tool developed by University at Buffalo researchers that can respond to medical questions, demonstrating high accuracy on medical licensing exams and augmenting physician decision-making.
Prenaital
Prenaital
Clinical Decision Support & Reference
Prenaital uses AI to detect and manage high-risk pregnancies, enhancing the detection of conditions like abnormal fetal growth, preterm birth, and stillbirth.
PHQ Screeners (Pfizer)
Pfizer
Clinical Decision Support & Reference
PHQ Screeners is a free, open-access resource providing validated Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments for depression and anxiety, widely used for diagnosis and monitoring.
Free
NeurixaHealthAI™
NeurixaHealthAI™
Clinical Decision Support & Reference
NeurixaHealthAI™ unifies fragmented patient data into a living population health engine to identify risk, close care gaps, and drive preventive interventions.
Contact for pricing

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.